Tesis Labs, a Phoenix, AZ-based targeted genetic sequencing company, raised $20m in growth equity financing at a post-money valuation of $520m.
The round was led by Xcellerant 1 TLC, an investment group headed by John Shufeldt, M.D.
The company intends to use the funds to increase production capability and clinical support and to move ahead with several clinical initiatives for its proprietary products currently going through clinical validation.
Led by Ron King, CEO and Managing Director, Tesis Labs offers healthcare providers and physicians access to genetic testing and precision medicine, enabling them to create personalized care plans for treating chronic diseases such as heart disease, lung disease, and cancer– individually and across generations.
The company also enables medical device companies and pharmaceuticals to bring new products to market and create a repository of genetic data and research.
FinSMEs
05/10/2021